Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.

[1]  E. Bruckert,et al.  Cardiovascular Disease Risk Associated With Familial Hypercholesterolemia: A Systematic Review of the Literature. , 2016, Clinical therapeutics.

[2]  G. Fonarow,et al.  Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States , 2016, Clinical cardiology.

[3]  G. Watts,et al.  Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. , 2016, Journal of the American College of Cardiology.

[4]  R. Giugliano,et al.  Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. , 2016, Journal of the American College of Cardiology.

[5]  G Villa,et al.  Avoiding Overestimation In Annualization of Event Risk from Risk Functions for use in Economic Modeling. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[7]  R. Ramos,et al.  Incident atrial fibrillation hazard in hypertensive population: a risk function from and for clinical practice. , 2015, Hypertension.

[8]  Philip R. Delio,et al.  Acute and chronic impact of cardiovascular events on health state utilities , 2015, BMC Health Services Research.

[9]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[10]  Barry J. Davis,et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[11]  E. Stein,et al.  A COMPREHENSIVE SAFETY ANALYSIS OF 6026 PATIENTS FROM PHASE 2 AND 3 SHORT AND LONG TERM CLINICAL TRIALS WITH EVOLOCUMAB (AMG 145) , 2015 .

[12]  Lesley Burgess,et al.  PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[13]  P. Scarborough,et al.  CardioPulse, Cardiovascular disease in Europe 2014: epidemiological update, Heart disease and stroke decline in Europe, Estimating an individual person's course of coronary artery calcification, The CardioScape Project, In memoriam , 2014 .

[14]  Daniel Prieto-Alhambra,et al.  Linking of Primary Care Records to Census Data to Study the Association between Socioeconomic Status and Cancer Incidence in Southern Europe: A Nation-Wide Ecological Study , 2014, PloS one.

[15]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[16]  G. Watts,et al.  Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. , 2014, Journal of the American College of Cardiology.

[17]  Jennifer G. Robinson,et al.  Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. , 2014, JAMA.

[18]  J. Cabasés,et al.  Self-Reported Population Health: An International Perspective based on EQ-5D , 2013 .

[19]  Peter Scarborough,et al.  Cardiovascular disease in Europe: epidemiological update. , 2014, European heart journal.

[20]  G. Watts,et al.  Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. , 2012, The Journal of clinical endocrinology and metabolism.

[21]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[22]  Deepak L. Bhatt,et al.  An international model to predict recurrent cardiovascular disease. , 2012, The American journal of medicine.

[23]  B. Bolibar,et al.  [SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research]. , 2012, Medicina clinica.

[24]  John Simes,et al.  Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy , 2012, PloS one.

[25]  E. Negri,et al.  Coronary heart disease and cerebrovascular disease mortality in young adults: recent trends in Europe , 2011, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[26]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[27]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[28]  Sarah Wordsworth,et al.  Applied Methods of Cost-Effectiveness Analysis in Healthcare , 2010 .

[29]  Jaume Puig-Junoy,et al.  Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias , 2010 .

[30]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[31]  Taghreed Adam,et al.  The burden and costs of chronic diseases in low-income and middle-income countries , 2007, The Lancet.

[32]  M. Miravitlles,et al.  Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura , 2007 .

[33]  J. A. Sacristán,et al.  Qué es una tecnología sanitaria eficiente en España , 2002 .

[34]  Andrew Briggs,et al.  An Introduction to Markov Modelling for Economic Evaluation , 1998, PharmacoEconomics.

[35]  Owen Smith,et al.  Public policy and the challenge of chronic noncommunicable diseases , 2007 .